Breaking News Instant updates and real-time market news.

AEHR

Aehr Test Systems

$3.15

0.3 (10.53%)

, SONC

Sonic

$27.57

-0.1 (-0.36%)

17:36
01/04/18
01/04
17:36
01/04/18
17:36

On The Fly: After Hours Movers

UP AFTER EARNINGS: Aehr Test Systems (AEHR), up 6%... Sonic (SONC), up 5.6%. ALSO HIGHER: WSI Industries (WSCI), up 15.7% after DPW Holdings reported a 7.76% stake in the company... Datawatch (DWCH), up 15.2% after Reuters reported that the company hired a financial adviser after drawing acquisition interest... ConforMIS (CFMS), up 13.5% after it said that a study shows that 100% of patients treated with iTotal CR achieve mechanical alignment in target range... YuMe (YUME), up 6.6% after RhythmOne plc commenced an exchange offer to acquire the company for cash and stock... Amarin (AMRN), up 5% after it provided preliminary 2017 results and 2018 outlook... T2 Biosystems (TTOO), up 2.8% after it guided for fourth quarter revenue above its prior forecast range... LexinFintech (LX), up 1.6% after KPartners disclosed a 14.4% stake in the company. DOWN AFTER EARNINGS: PriceSmart (PSMT), down 6.7%. ALSO LOWER: Francesca's (FRAN), down 16.4% after it lowered its Q4 guidance and provided FY17 guidance... Regenxbio (RGNX), down 16.3% after it guided for fiscal 2018 cash burn of $85M-$95M... Novan (NOVN), down 10.4% after filing to sell common stock and warrants... OncoMed (OMED), down 9.6% after CEO Paul Hastings resigned... Scynexis (SCYX), down 9.1% after it said it plans to restart clinical trials with IV SCY-078 in Q3... Oneok (OKE), down 3.6% after filing to sell 19M shares of common stock... AveXis (AVXS), down 0.7% after it said it was aligned with the FDA on the next step toward a BLA submission for AVXS-101.

AEHR

Aehr Test Systems

$3.15

0.3 (10.53%)

SONC

Sonic

$27.57

-0.1 (-0.36%)

WSCI

WSI Industries

$6.04

-0.01 (-0.17%)

DWCH

Datawatch

$9.20

-0.25 (-2.65%)

CFMS

ConforMIS

$2.38

0.02 (0.85%)

YUME

YuMe

$4.69

0.12 (2.63%)

AMRN

Amarin

$4.19

(0.00%)

TTOO

T2 Biosystems

$4.67

0.03 (0.65%)

LX

LexinFintech

$14.74

-0.65 (-4.22%)

PSMT

PriceSmart

$87.85

1.45 (1.68%)

FRAN

Francesca's

$7.50

(0.00%)

RGNX

Regenxbio

$35.20

-0.6 (-1.68%)

NOVN

Novan

$4.24

-0.06 (-1.40%)

OMED

OncoMed

$3.98

0.08 (2.05%)

SCYX

Scynexis

$2.42

0.09 (3.86%)

OKE

Oneok

$56.20

0.66 (1.19%)

AVXS

AveXis

$104.74

-1.9 (-1.78%)

  • 04

    Jan

  • 04

    Jan

  • 04

    Jan

  • 04

    Jan

  • 05

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 08

    Jan

  • 09

    Jan

  • 26

    Feb

  • 05

    Jan

  • 05

    Jan

AEHR Aehr Test Systems
$3.15

0.3 (10.53%)

04/05/17
MAXM
04/05/17
NO CHANGE
MAXM
Aehr Test Systems a 'clear beneficiary' of new iPhone features, says Maxim
Maxim analyst Nehal Chokshi said that, as with each new iPhone generation, Apple's (AAPL) implementing of new capabilities requires an increasing bill of materials cost, which will again pressure its gross margins. Noting there will be "many supply chain winners due to the added functionality," Chokshi highlighted AEHR Test Systems (AEHR) as a clear direct beneficiary since it uniquely provides a wafer-level burn-in testing tool that is used by Apple. Additionally, he identifies Intevac (IVAC) as "at least a second order beneficiary" as Apple's reported plans for wireless charging in the iPhone 8 should spur industry adoption, helping to double the company's oDLC opportunity to $1B over the next five years.
SONC Sonic
$27.57

-0.1 (-0.36%)

09/28/17
BARD
09/28/17
NO CHANGE
Target $20
BARD
Neutral
Sonic breach not material risk to processor First Data, says Baird
Baird analyst David Koning believes First Data (FDC) is the card processor for Sonic (SONC), which reported a security breach yesterday. The analyst believes it is possible the franchised locations of Sonic use different processors, so he does not view the breach as a material risk to First Data. Koning maintained his Neutral rating and $20 price target on First Data shares.
01/04/18
OPCO
01/04/18
DOWNGRADE
OPCO
Perform
Sonic downgraded to Perform from Outperform at Oppenheimer
10/06/17
OPCO
10/06/17
NO CHANGE
Target $29
OPCO
Outperform
Sonic outlook to keep shares 'stalled' near term, says Oppenheimer
Oppenheimer analyst Brian Bittner expects Sonic's initial 2018 earnings outlook on October 16 to keep the shares "stalled" i in the near term. The analyst believes 2018 consensus estimates are "skewed a bit aggressively." His estimates are 5% below the Street. Bittner, however, see limited downside risk to Sonic shares without "significant" negative earnings revisions. He keeps an Outperform rating on the stock with a $29 price target.
01/04/18
OPCO
01/04/18
DOWNGRADE
OPCO
Perform
Sonic downgraded to Perform from Outperform at Oppenheimer
Oppenheimer analyst Brian Bittner downgraded Sonic to Perform and removed his $29 price target on the shares. The analyst sees "limited catalysts from here" with the stock up 15% in a month. He sees above-average risk to the Street's same-store-sales and margins estimates in 2018.
WSCI WSI Industries
$6.04

-0.01 (-0.17%)

DWCH Datawatch
$9.20

-0.25 (-2.65%)

04/21/17
04/21/17
UPGRADE
Target $11.5

Buy
Datawatch upgraded to Buy from Neutral at National Securities
National Securities analyst Ilya Grozovskyupgraded Datawatch to Buy with an $11.50 price target citing more consistent revenue growth following the company's Q2 report.
04/21/17
CHLM
04/21/17
NO CHANGE
Target $13
CHLM
Buy
Time to buy Datawatch, says Craig-Hallum
After the company reported its third consecutive quarter of revenue growth, Craig-Hallum analyst Chad Bennett thinks it is time to buy Datawatch given accelerating growth, positive operating cash flow and a large opportunity ahead. The analyst reiterated a Buy rating on the stock and raised his price target on the shares to $13 from $10.
CFMS ConforMIS
$2.38

0.02 (0.85%)

12/20/17
12/20/17
UPGRADE
Target $4

Buy
ConforMIS upgraded to Buy at BTIG
As previously reported, BTIG analyst Ryan Zimmerman upgraded ConforMIS to Buy from Neutral, with a $4 price target, saying that while it still needs to improve production times, increase margins, and grow faster, at this valuation the risk/reward is favorable. Further, the analyst believes the strategies management has undertaken over the previous year could begin to bear fruit in FY18 and any return to growth will begin to lift shares.
01/02/18
JPMS
01/02/18
DOWNGRADE
JPMS
Underweight
ConforMIS downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Michael Weinstein downgraded ConforMIS to Underweight without a price target. The analyst finds it "tough" to recommend owning the stock in 2018 given the company's cash burn, limited sales growth and the potential for additional financing at some point in the next 12 months.
08/04/17
DBAB
08/04/17
DOWNGRADE
Target $5
DBAB
Hold
ConforMIS downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Brittany Henderson downgraded ConforMIS to Hold and trimmed its price target to $5 from $6 following the Q2 miss and reduced full year outlook and said changes in the company's commercial strategy could take longer to play out than previously expected.
12/20/17
BTIG
12/20/17
UPGRADE
BTIG
Buy
ConforMIS upgraded to Buy from Neutral at BTIG
YUME YuMe
$4.69

0.12 (2.63%)

AMRN Amarin
$4.19

(0.00%)

12/20/17
CANT
12/20/17
NO CHANGE
Target $10
CANT
Overweight
Cantor more confident in $10 target for Amarin after management meetings
Cantor Fitzgerald analyst Louise Chen says that after spending two days with management, she has increased confidence in her Overweight rating and $10 price target for Amarin shares. The analyst believes the company's Vascepa can help lower deaths and the cost of care for patients with high triglycerides levels without increasing LDL-C. Chen believes this is still underappreciated in Amarin shares.
12/14/17
CANT
12/14/17
NO CHANGE
Target $10
CANT
Overweight
Cantor sees Vascepa benefits driving Amarin shares higher
Research recently presented to the American Heart Association by a key opinion leader showed over-the-counter fish oil supplements may contain mercury, are high in saturated fats and sugar, and may even raise lipid levels and deplete antioxidants, Cantor Fitzgerald analyst Louise Chen wrote yesterday in a research note titled "Something Smelly about Unregulated Fish Oil Contaminants." FDA approved products, such as Amarin's Vascepa, were found to be pure and safe, Chen adds. The research reinforced her view that the "differentiation and scientific benefit" of Vascepa will drive shares of Amarin higher. The analyst kept an Overweight rating on Amarin shares with a $10 price target.
08/03/17
HCWC
08/03/17
NO CHANGE
Target $10
HCWC
Buy
Amarin valuation attractive into interim data, says H.C. Wainwright
Amarin's current valuation is supported by the "strong" underlying Vascepa sales alone, H.C. Wainwright analyst Andrew Fein tells investors in a post-earnings research note. He believes the recent share pullback provides an opportunity for a "free shot" at the upcoming interim look of the REDUCE-IT trial. Investors are ascribing no value to the interim nor full study at all, the analyst contends. He reiterates a Buy rating on Amarin with a $10 price target.
08/29/17
CANT
08/29/17
NO CHANGE
Target $10
CANT
Overweight
Cantor positive on Amarin after Novartis study results
Cantor Fitzgerald analyst Louise Chen believes the Phase 3 CANTOS study results from Novartis (NVS) support the hypothesis that a long-term drug treatment focused on an anti-inflammatory mechanism in patients with a prior heart attack and inflammatory atherosclerosis can reduce cardiovascular events. In two Phase 3 trials, Amarin's (AMRN) Vascepa affected inflammatory markers including hsCRP and Lp-PLA2 while also improving lipid biomarkers, Chen tells investors in a research note. CANTOS and other recently reported studies help to increase her confidence in a positive and commercial outcome for Amarin's REDUCE-IT trial. The analyst has an Overweight rating on the shares with a $10 price target.
TTOO T2 Biosystems
$4.67

0.03 (0.65%)

03/14/17
MSCO
03/14/17
DOWNGRADE
Target $5
MSCO
Underweight
T2 Biosystems downgraded to Underweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Steve Beuchaw downgraded T2 Biosystems to Underweight and lowered his price target for the shares to $5 from $6. The company last week disclosed that its CFO Shawn Lynch resigned effective immediately. Lynch indicated that he resigned for personal reasons and that his resignation was not the result of any disagreement with the management or the board, T2 added. The stock closed the trading day unchanged at $6.07.
09/11/17
09/11/17
NO CHANGE

T2 Biosystems submits 510(k) application to FDA for review of T2Bacteria panel
T2 Biosystems announced that it has filed a 510(k) premarket submission for the T2Bacteria Panel with the FDA. The T2Bacteria Panel is designed to run on the FDA-cleared T2Dx Instrument. The T2Bacteria Panel, once FDA cleared, combined with the commercially available T2Candida Panel is designed to be the first comprehensive rapid diagnostic solution on the market that identifies pathogens associated with sepsis within hours instead of days, potentially enabling 95% of patients with bloodstream infections to receive targeted therapy within 8 hours of blood draw.
05/08/17
BTIG
05/08/17
UPGRADE
Target $4
BTIG
Neutral
T2 Biosystems upgraded to Neutral from Sell at BTIG
BTIG analyst Karen Koski upgraded T2 Biosystems to Neutral saying shares have fallen below her prior $4 price target and believes the upcoming panel for T2Bacteria will act as a positive catalyst.
10/18/17
HCWC
10/18/17
INITIATION
Target $8
HCWC
Buy
T2 Biosystems initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju started T2 Biosystems with a Buy rating and $8 price target. The company, by targeting blood stream infections within the $60B in vitro diagnostics market, could generate peak sales of approximately $770M in 2035, the analyst contends.
LX LexinFintech
$14.74

-0.65 (-4.22%)

PSMT PriceSmart
$87.85

1.45 (1.68%)

10/02/17
ROTH
10/02/17
NO CHANGE
Target $100
ROTH
Buy
Hurricanes likely to weigh on PriceSmart September sales, says Roth Capital
Roth Capital analyst Dave King says PriceSmart may capture incremental sales from the stockpiling of goods ahead of recent hurricanes, but his analysis of estimated store closures and sourcing and distribution dislocations suggests the net impact may be negative. While longer-term investors should look past these short-term trends, the analyst notes shares have rallied about 10% since the beginning of September when expectations for stockpiling first emerged. King reiterates a Buy rating on the shares, while lowering his price target on the stock to $100 from $102.
12/29/17
IFSG
12/29/17
UPGRADE
IFSG
Outperform
PriceSmart upgraded to Outperform from Market Perform at IFS Securities
12/29/17
12/29/17
NO CHANGE

On The Fly: Top five analyst actions
Catch up on today's top five analyst actions with this list compiled by The Fly: 1. AstraZeneca (AZN) upgraded to Overweight from Neutral at JPMorgan with analyst James Gordon saying the company's "superior medium-term growth outlook," which is twice the peer average, warrants a 25% sector premium. 2. PriceSmart (PSMT) upgraded to Outperform from Market Perform at IFS Securities. 3. Novo Nordisk (NVO) upgraded to Neutral from Underweight at JPMorgan with analyst Richard Vosser saying he expects "strong" oral semaglutide Phase III newsflow in 2018. 4. Syntel (SYNT) downgraded to Underperform from Market Perform at Wells Fargo with analyst Ed Caso saying he sees the company's "weak" positioning for the ongoing shift in information technology demand from "legacy" low-cost offshore-centric software services to more onshore-necessary "digital" solutions as dragging down its growth and margins. 5. RioCan REIT downgraded to Sector Perform from Outperform at RBC Capital. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/29/17
12/29/17
UPGRADE
Target $100

Outperform
PriceSmart upgraded to Outperform ahead of earnings at IFS Securities
As previously reported, IFS Securities analyst Ronald Bookbinder upgraded PriceSmart to Outperform from Market Perform ahead of the company's earnings report, which is due Thursday, January 4. He expects Q1 results to be in-line to slightly below consensus, but also predicts a more promising outlook given higher oil prices, better Colombian operations and the improving U.S. economy. Bookbinder raised his price target on PriceSmart shares to $100 from $85.
FRAN Francesca's
$7.50

(0.00%)

05/31/17
05/31/17
UPGRADE
Target $14

Market Perform
Francesca's upgraded to Market Perform from Underperform at FBR Capital
FBR Capital analyst Susan Anderson upgraded Francesca's to Market Perform citing valuation and the stabilization of promotions. The analyst has a $14 price target for the shares.
08/15/17
08/15/17
NO CHANGE

FBR lowers Specialty Retail price targets ahead of Q2 reports
FBR Capital analyst Susan Anderson expects Specialty Retail earnings in Q2 to be overall in-line with consensus estimates, with a lighter top line and gross margin given the need to promote to drive traffic. The analyst views American Eagle (AEO) and L Brands (LB) as winners in the quarter. She upgraded American Eagle this morning to Buy. Anderson also lowered her price target for Neutral-rated Abercrombie & Fitch (ANF) to $11 from $13, for Neutral-rated Ascena Retail (ASNA) to $3 from $5, for Neutral-rated Foot Locker (FL) to $58 from $66, for Neutral-rated Francesca's to $10 from $13, for Neutral-rated Gap (GPS) to $25 from $28 and for Neutral-rated Urban Outfitters (URBN) to $16 from $24.
08/22/17
RHCO
08/22/17
NO CHANGE
RHCO
Francesca's should be bought on weakness, says SunTrust
SunTrust analyst Pamela Quintiliano notes that Francesca's Q2 results beat expectations, but its comps were "at the low end of expectations," while its Q3 "trends have decelerated and its CMO has departed." The analyst cut her price target on the shares to $10 from $15, saying that she expects its "challenges to persist near-term." However, the analyst thinks that the company's "quick lead times and tight inventory controls" should improve its business during the holidays. She recommends buying the shares on weakness and reiterates a Buy rating.
RGNX Regenxbio
$35.20

-0.6 (-1.68%)

11/09/17
MSCO
11/09/17
INITIATION
Target $34
MSCO
Overweight
Regenxbio resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Matthew Harrison resumed coverage of Regenxbio with an Overweight rating and a $34 price target, saying he expects updates from its Phase 1 studies of RGX-501 and RGX-314 in early January to be the next catalysts for the stock.
11/09/17
11/09/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. AnaptysBio (ANAB) initiated with a Buy at Jefferies. 2. Regenxbio (RGNX) resumed with an Overweight at Morgan Stanley. 3. GTx (GTXI) initiated with a Buy at Stifel. 4. Idera Pharmaceuticals (IDRA) initiated with a Buy at H.C. Wainwright. 5. Nektar (NKTR) initiated with a Buy at Canaccord. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/22/17
LEHM
11/22/17
INITIATION
Target $38
LEHM
Overweight
Regenxbio initiated with an Overweight at Barclays
Barclays analyst Gena Wang started Regenxbio with an Overweight rating and $38 price target. The analyst views the company's patent portfolio as "strong" and sees "significant upside" from its wholly owned RGX-314 program in wet age-related macular degeneration.
11/22/17
11/22/17
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Nutanix (NTNX) initiated with a Buy at Needham. 2. Regenxbio (RGNX) and Sangamo (SGMO) were initiated with an Overweight at Barclays. 3. Amedisys (AMED), HealthSouth (HLS), LHC Group (LHCG), and LifePoint (LPNT) were initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
NOVN Novan
$4.24

-0.06 (-1.40%)

04/12/17
PIPR
04/12/17
NO CHANGE
Target $11
PIPR
Overweight
Novan price target raised to $11 after athlete's foot gel data at Piper Jaffray
Piper Jaffray analyst David Amsellem raised his price target on Novan to $11 to $9 after the company reported topline results from its Phase 2 trial of its silicone based-gel under development for the treatment of athlete's foot. He maintains an Overweight rating on Novan shares.
05/12/17
05/12/17
NO CHANGE

Novan reports Q1 EPS (73c), consensus (49c)
Reports Q1 revenue $100K, consensus $3.6M.
01/27/17
WEDB
01/27/17
DOWNGRADE
WEDB
Neutral
Novan downgraded to Neutral from Outperform at Wedbush
OMED OncoMed
$3.98

0.08 (2.05%)

04/17/17
RHCO
04/17/17
DOWNGRADE
RHCO
Hold
OncoMed downgraded to Hold from Buy at SunTrust
04/17/17
PIPR
04/17/17
DOWNGRADE
Target $5
PIPR
Neutral
Piper downgrades OncoMed after second failed study
Piper Jaffray analyst Edward Tenthoff downgraded OncoMed Pharmaceuticals to Neutral from Overweight after the company's Phase II tarextumab study in first-line small cell lung cancer failed. The analyst cut his price target for the shares to $5 from $17. The trial failure follows last week's negative Phase II data on demcizumab in first-line pancreatic cancer last week, Tenthoff tells investors in a research note. OncoMed in morning trading is down 20% to $3.86.
07/10/17
PIPR
07/10/17
NO CHANGE
Target $5
PIPR
Neutral
OncoMed termination from GSK not surprising, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff believes GlaxoSmithKline (GSK) terminating its agreement with OncoMed Pharmaceuticals (OMED) is not surprising since tarextumab, the only remaining asset under the collaboration, failed previously to meet the primary endpoint in a Phase II study for first-line small cell lung cancer. The analyst says he remains focused on OncoMed's early stage pipeline including navicixizumab, rosmantuzumab and I/O assets anti-TIGIT and GITR trimer. Tenthoff keeps a Neutral rating on OncoMed with a $5 price target.
04/17/17
JMPS
04/17/17
DOWNGRADE
JMPS
Market Perform
OncoMed downgraded to Market Perform from Outperform at JMP Securities
SCYX Scynexis
$2.42

0.09 (3.86%)

10/24/17
GUGG
10/24/17
INITIATION
Target $6
GUGG
Buy
SCYNEXIS initiated with a Buy at Guggenheim
Guggenheim analyst Adnan Butt initiated SCYNEXIS with a Buy and $6 price target.
05/09/17
05/09/17
DOWNGRADE

Hold
SCYNEXIS downgraded to Hold at Needham
As previously reported, Needham analyst Alan Carr downgraded SCYNEXIS to Hold from Buy after the company announced in a quarterly update that FDA has requested additional information to better understand IV SCY-078 risk for thrombosis. Although Scynexis may continue development of the oral formulation, the analyst believes FDA action around IV formulation is disruptive to overall SCY-078 strategy.
07/10/17
07/10/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. SeaSpine (SPNE) initiated with a Buy at H.C. Wainwright. 2. Puma Biotechnology (PBYI) resumed with an Outperform at Leerink. 3. SCYNEXIS (SCYX) initiated with a Buy at Roth Capital. 4. Tabula Rasa HealthCare (TRHC) initiated with a Buy at Chardan. 5. Matinas BioPharma (MTNB) initiated with a Buy at Roth Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/10/17
ROTH
07/10/17
INITIATION
Target $8.5
ROTH
Buy
SCYNEXIS initiated with a Buy at Roth Capital
Roth Capital analyst Michael Higgins started SCYNEXIS with a Buy rating and $8.50 price target.
OKE Oneok
$56.20

0.66 (1.19%)

01/04/18
USCA
01/04/18
UPGRADE
USCA
Buy
Oneok upgraded to Buy from Overeight at US Capital Advisors
09/11/17
JPMS
09/11/17
UPGRADE
Target $58
JPMS
Neutral
Oneok reinstated with a Neutral from Underweight at JPMorgan
JPMorgan analyst Jeremy Tonet upgraded Oneok to Neutral and raised his price target on the shares to $58 from $48 following a period of restriction. He believes the company's possesses the "premier NGL value chain" from North Dakota to Texas.
09/05/17
LEHM
09/05/17
INITIATION
Target $58
LEHM
Equal Weight
Oneok reinstated with an Equal Weight at Barclays
Barclays analyst Christine Cho reinstated coverage of Oneok with an Equal Weight rating and $58 price target.
07/06/17
MSCO
07/06/17
INITIATION
Target $54
MSCO
Equal Weight
Oneok initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Tom Abrams resumed coverage on Oneok with an Equal Weight and a $54 price target saying risk/reward appears balanced.
AVXS AveXis
$104.74

-1.9 (-1.78%)

10/12/17
JEFF
10/12/17
NO CHANGE
Target $118
JEFF
Buy
AveXis price target raised to $118 from $108 at Jefferies
Jefferies analyst Biren Amin raised his price target for AveXis (AVXS) to $118 after hosting an spinal muscular atrophy expert to discuss the current landscape of therapies. While Biogen (BIIB) and Ionis Pharmaceuticals' (IONS) Spinraza seems to be performing well, the expert believes AveXis' AVXS-101 could capture between 60%-80% share in Type 1 once approved, Amin tells investors in a research note. The expert does not believe there will be enrollment issues for AveXis' pivotal trial in Type 1 SMA, the analyst adds. Amin keeps a Buy rating on AveXis shares.
10/12/17
BMOC
10/12/17
NO CHANGE
Target $130
BMOC
Outperform
AveXis price target raised to $130 from $123 at BMO Capital
BMO Capital analyst M. Ian Somaiya raised the price target on AveXis (AVXS) to $130 and maintained his Outperform rating on the stock. The analyst is moving forward his expectations for the launch of AVXS-101 for Type 1 spinal muscular atrophy by 12 months to the second half of FY18 based on the comparison of event-free survival data suggesting AveXis' product is superior to those of Biogen (BIIB) / Ionis (IONS)'s Spinraza. Somaiya says the end of Phase I meeting in Q4 will confirm an accelerated filing strategy in Type 1 SMA patients.
10/26/17
ADAM
10/26/17
INITIATION
Target $110
ADAM
Hold
AveXis initiated with a Hold at Canaccord
Canaccord initiated AveXis with a Hold and $110 price target.
11/10/17
RBCM
11/10/17
NO CHANGE
Target $97
RBCM
Sector Perform
AveXis price target raised to $97 from $92 at RBC Capital
RBC Capital analyst Brian Abrahams raised his price target on AveXis to $97 after Q3 earnings, noting the quarter saw good progress in '101 on the clinical and regulatory fronts. The analyst says he now awaits Q1 updates for "comfort on potential for rapid timelines", adding that shares fairly balance the '101 approval potential with intrinsic market complexities.

TODAY'S FREE FLY STORIES

12:05
08/20/18
08/20
12:05
08/20/18
12:05
General news
Fed's Bostic said the economy doesn't need as much stimulus as it did before »

Fed's Bostic said…

AVNW

Aviat Networks

$16.20

(0.00%)

12:04
08/20/18
08/20
12:04
08/20/18
12:04
Hot Stocks
Aviat Networks introduces online selling with new Aviat store »

Aviat Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CFBK

Central Federal

$2.52

(0.00%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Central Federal announces 1-for-5.5 reverse stock split »

Central Federal…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TAHO

Tahoe Resources

$3.84

0.06 (1.59%)

12:03
08/20/18
08/20
12:03
08/20/18
12:03
Hot Stocks
Tahoe Resources terminates approx. 200 additional Minera San Rafael employees »

Tahoe Resources regrets…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BE

Bloom Energy

$22.66

0.44 (1.98%)

12:01
08/20/18
08/20
12:01
08/20/18
12:01
Hot Stocks
Street Fight: Analysts split on Bloom Energy after IPO »

Several Wall Street…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRK

Comstock Resources

$8.26

-0.46 (-5.28%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Comstock Resources falls -5.1% »

Comstock Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBP

Installed Building Products

$46.80

-2.55 (-5.17%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Installed Building Products falls -5.3% »

Installed Building…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 21

    Aug

  • 06

    Nov

LCI

Lannett

$5.55

-7.95 (-58.89%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Lannett falls -58.7% »

Lannett is down -58.7%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 28

    Aug

CATM

Cardtronics

$37.25

0.08 (0.22%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Options
Second day of call buying in Cardtronics »

Second day of call buying…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATV

Acorn International

$22.00

3.14 (16.65%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Acorn International rises 8.7% »

Acorn International is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMRX

Amneal Pharmaceuticals

$23.96

2.43 (11.29%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Amneal Pharmaceuticals rises 11.5% »

Amneal Pharmaceuticals is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 12

    Sep

CMCM

Cheetah Mobile

$10.85

1.75 (19.23%)

12:00
08/20/18
08/20
12:00
08/20/18
12:00
Hot Stocks
Cheetah Mobile rises 19.5% »

Cheetah Mobile is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

PCG

PG&E

$45.05

-0.195 (-0.43%)

, EIX

Edison International

$69.44

-0.42 (-0.60%)

11:59
08/20/18
08/20
11:59
08/20/18
11:59
Periodicals
California's Dodd says securitization of PG&E liability mulled, Bloomberg says »

California Senator Bill…

PCG

PG&E

$45.05

-0.195 (-0.43%)

EIX

Edison International

$69.44

-0.42 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

IMTE

Integrated Media Technology

$12.20

0.2 (1.67%)

11:58
08/20/18
08/20
11:58
08/20/18
11:58
Hot Stocks
Integrated Media unit enters distribution agreement with Ai Holdings »

Integrated Media…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$106.76

-0.82 (-0.76%)

11:57
08/20/18
08/20
11:57
08/20/18
11:57
Hot Stocks
Skype's end-to-end encrypted Private Conversations now available for all users »

Microsoft's Skype…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 12

    Sep

TSLA

Tesla

$302.49

-2.84 (-0.93%)

11:55
08/20/18
08/20
11:55
08/20/18
11:55
Recommendations
Tesla analyst commentary  »

Tesla may be wise to try…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

TSLA

Tesla

$302.35

-2.98 (-0.98%)

11:52
08/20/18
08/20
11:52
08/20/18
11:52
Periodicals
Tesla's lawyers believe SEC 'under pressure' to expdite probe, Gasparino tweets »

FBN's Charles…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

PX

Praxair

$157.81

1.86 (1.19%)

, LNEGY

Linde

$0.00

(0.00%)

11:51
08/20/18
08/20
11:51
08/20/18
11:51
Hot Stocks
EU approves proposed merger between Linde, Praxair »

The European Commission…

PX

Praxair

$157.81

1.86 (1.19%)

LNEGY

Linde

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$285.40

0.38 (0.13%)

11:50
08/20/18
08/20
11:50
08/20/18
11:50
Options
Continued interest in end of year call spreads in SPDR 500 Trust options »

Continued interest in end…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:50
08/20/18
08/20
11:50
08/20/18
11:50
General news
Treasury's $96 B 3- and 6-month bill sale was ok »

Treasury's $96 B 3-…

XLU

Utilities SPDR

$54.43

-0.07 (-0.13%)

11:40
08/20/18
08/20
11:40
08/20/18
11:40
Options
Opening call write in SPDR Utility ETF »

Opening call write in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
3-Month Bill Auction Total Amount data reported »

3-Month Bill Auction…

11:36
08/20/18
08/20
11:36
08/20/18
11:36
General news
6-Month Bill Auction Total Amount data reported »

6-Month Bill Auction…

IMNP

Immune Pharmaceuticals

$0.00

(0.00%)

11:36
08/20/18
08/20
11:36
08/20/18
11:36
Hot Stocks
Immune Pharmaceuticals granted Orphan Drug Designation for bertilimumab »

Immune Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

RIG

Transocean

$11.23

0.47 (4.37%)

11:30
08/20/18
08/20
11:30
08/20/18
11:30
Options
Notable call buyer in Transocean »

Notable call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.